Issue 66

Psychedelic profiles: LSD

Lysergic acid diethylamide is a synthetic serotonergic psychedelic. It binds to both serotonin and dopamine receptors, in key contrast to psilocybin, and its effects are noticeable at dosages measured in the millionths of a gram.

In November 1938, Albert Hofmann synthesised LSD-25 for the first time. By 1947, it was introduced as a psychiatric medication under the trade name Delysid by Sandoz and was found to disrupt negative thought patterns.

Although less intensely studied since the turn of the century, LSD has played a pivotal role in psychedelic research and the discovery of serotonin receptors in the brain.

EXPLORE OUR PSYCHEDELIC SERIES

SHOULD PSYCHEDELICS BE MORE WIDELY AVAILABLE?

The Economist spoke with Dr Marks from Harvard about the possibility of Oregon’s decriminalisation measures being replicated.

Read More

VIRGINIA DECRIMINALISATION BILL DEFEATED IN SENATE

A bill to decriminalise psilocybin-assisted therapy in Virginia has stalled after failing to gather enough support in the General Assembly.

Read More

BUSINESS AND INVESTMENT

Novamind closes C$5m private placement.

Tryp reports Q1 2022 financial results.

Cybin and Filament Health gain approval for Phase II trial.

atai creates subsidiary Invyxis to expand drug discovery.

PharmaTher granted orphan drug designation.

How AI could unlock the medical potential of psychedelics.

Nova Mentis partners with KGK Science on psilocybin programme.

At the PSYCH Investor Summit, Field Trip’s Founder Ronan Levy, MINDCURE’s CEO Kelsey Ramsden and Novamind’s Chief Medical Officer Dr Reid Robison discussed the adoption of applications that monitor patients before, during and after psychedelic assisted therapy.

View the panel discussion

SCIENCE AND RESEARCH

Flashback phenomena after administration of LSD and psilocybin.

Psychedelic therapy shows great promise.

Structure-based discovery of non-hallucinogenic psychedelic analogs.

Psychedelic therapy benefits for mental health.

Clinical study of psychedelic drugs for cancer patients could be a ‘game changer’.

REGULATION AND LEGISLATION

US court of appeals rejects cancer patients’ case to access psilocybin.

Michigan activists file psychedelic decriminalisation ballot initiative.

Ballot in Colorado revised to establish licensed psychedelic therapy centres.

Colorado activists file competing decriminalisation bill.

Oregon lawmakers file psilocybin equity bill.

Partner with us